Is S-1 medication better than radiation alone for elderly patients with esophageal squamous cell carcinoma?

For elderly patients (70 years and older) with inoperable esophageal squamous cell carcinoma (ESCC), the standard treatment often involves radiation therapy. However, adding chemotherapy can be challenging due to age and other health issues. A large clinical trial directly compared S-1 (an oral chemotherapy drug) combined with radiation versus radiation alone. The results show that the combination therapy leads to better long-term survival and cancer control.

What the research says

A multicenter phase III randomized trial in China enrolled patients aged 70 years and older with inoperable, locally advanced ESCC ³⁹¹⁰. Patients were randomly assigned to receive either simultaneous integrated boost radiotherapy (SIB-RT) alone or SIB-RT combined with oral S-1 chemotherapy (given during and after radiation) ³⁹¹⁰. After a median follow-up of 75 months, the combination group had significantly longer overall survival (hazard ratio 0.74) and higher 5-year survival rates (34.1% vs. 23.6%) ³¹⁰. Progression-free survival was also better (31.1% vs. 20.9% at 5 years) ³¹⁰. Locoregional failure (cancer returning in the same area) was lower in the combination group, while distant failure rates were similar ³¹⁰. The researchers concluded that S-1-based chemoradiotherapy should be considered a standard of care for these patients ³⁹¹⁰.

What to ask your doctor

• Based on my age and overall health, am I a candidate for S-1 plus radiation instead of radiation alone?
• What are the potential side effects of adding S-1 to radiation, and how can they be managed?
• How does the survival benefit shown in the trial compare to other treatment options for my specific stage of esophageal cancer?
• Are there any other factors, such as kidney function or other medications, that might affect whether S-1 is safe for me?
• What is the typical schedule for S-1 treatment (concurrent and consolidation) and how long would I need to take it?